INTRODUCTION
Neuroendocrine tumors (NET) were previously called carcinoid tumors (1) . NET can be divided into five types of tumors according to World Health Organization (WHO) classification of tumors of the digestive system, 2010 : NET G1, NET G2, neuroendocrine carcinoma (NEC) (large cell or small cell type), mixed adenoneuroendocrine carcinoma (MANEC), and hyperplastic and preneoplastic lesions (2) . Most cases are classified into former three groups. NET is a rare neoplasm that includes carcinoid, neuroendocrine carcinoma and small cell carcinoma. G stands for grading according to mitotic count and Ki-67 index. NET G1 is usually benign, whereas NET G2 and NEC are malignant. Tumor capacity is measured by Ki-67 staining with Ki-67 index != 2% seen in G1 tumors, 3% -20% in G2 tumors, and "20% tumor cell involvement in NEC (2) . NEC is a relatively rare tumor in the stomach (3, 4) . It exhibits aggressive growth which results in vascular invasion and early distant metastasis, and has a poor prognosis (5, 6) .
Here we report a case of NET G2 in the stomach that showed an intriguing endoscopic finding.
CASE REPORT
A 61 -year -old Japanese male patient presented with a 1 -month history of abdominal fullness. Patient interview revealed no particular past history, family history or social history. On physical examination, right upper quadrant or epigastric hard mass was easily palpable. A blood laboratory test showed anemia (hemoglobin 10.5 g/dl), hyperleukocytosis (10,800/mm 3 with 7,660/mm 3 of neutrophils), raised C -reactive protein (3.3 mg/dl) and elevated erythrocyte sedimentation rate (64 mm/hour). Serum CEA and CA19 -9 were within normal range. Examination by esophagogastroduodenoscopy revealed a whitish cauliflower -shaped Borrmann type I tumor on the lesser curvature of the gastric antrum ( Fig. 1) . Histological biopsies of the lesion revealed the diagnosis of NET G2. Computed tomography (CT) showed a gastric tumor with another big mass which seems to be a lymphadenopathy around the posterior of the hepatic left lobe and epigastric lesion (Fig. 2) . Whole body positron emission tomography (PET)/CT image demonstrates an intense uptake of 18F-fluoro-2 -deoxyglucose (FDG) in the lesser curvature of the stomach (SUVmax 10.4) and in several perigastric lymph nodes (SUVmax 5.3), but did not detect any distant metastasis. Endoscopic and transabdominal ultrasonography (EUS) showed an isoechoic tumor mainly in the mucosal and submucosal layer and the tumor developed into deeper layer (Fig.  3 ). He underwent a distal gastrectomy with D2 lymphadenectomy. A Billroth type I anastomosis was done. The resected tumor showed Borrmann type I mass 6! 7 cm in size. Microscopically, the tumor was composed of malignant large cells with rich cytoplasm, and large, round, clear nuclei. The tumor cells were arranged to form solid nests or sheet-like structures. Immunohistochemical analysis revealed that the tumor cells were positive for CD56 and synaptophysin, but negative for chromogranin A (Fig. 4) . The tumor had infiltrated the subserosal layer and lymph node metastasis was found in 6 of 42 lymph nodes. The Ki-67 labeling index was 10%. These findings led to the diagnosis of NET G2 according to the 2010 WHO criteria. His performance status (PS) has been 3 after operation. Therefore, he was not treated by adjuvant chemotherapy. His PS improved into 1 by inpatient and outpatient 
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hospital treatment, but liver and lymph node metastases were revealed by follow up computed tomography 11 months later. Biweekly irinotecan (CPT-11) plus cisplatin (CDDP) chemotherapy (CPT-11 60 mg/m 2 and CDDP 30 mg/m 2 on day 1) was treated since then. The patient had a partial response at first and received them for 9 months. His anorexia and liver injury got worse into grade 3 and the chemotherapy was impossible to be continued. The tumor was regrown and he died of multiple hepatic metastases after 31 months from operation.
DISCUSSION
Gastric NEC is a rare tumor, which reportedly comprises 0.1-0.6% of gastric cancers (3, 7, 8) . NEC is deeply invasive and metastatic. The diagnostic rate by biopsies under esophagogastroduodenoscopy is very low (11-27%) (9, 10), because the tumors of most cases contain adenocarcinoma components. The biopsied specimen of our case was immune -stained positively with synaptophysin and CD56. It comprises NET G2 and seems to be classified as a pure type according to the pathological examination of the resected tumor (5). The Ki-67 labeling index of this tumor was 10% in the component and the diagnosis was NET G2 according to the 2010 WHO classification. But the growth was very progressive and invasive. The clinical course of our case seems to be defined as carcinoma. Spampatti et al. (11) reported the case of gastric NET G1 with 6 mm in size and a Ki-67 of less than 2% which proceeded into 7 cm of NEC with both hepatic and massive peritoneal metastases (Ki-67 40%) after 8 years. Gastric NET G1 or G2 may have a malignant potential and should be followed up carefully. Large cell neuroendocrine carcinoma of the stomach is rare and also a small percentage of all gastric endocrine tumors (12) . It is significantly more aggressive than that of gastric adenocarcinoma (12) . Pathological examination of this component in our case is large cell type. The clinical course of large cell type NET G1 or G2 may be similar with gastric NEC.
Rindi et al. (13) classified gastric NETs into three types based on the clinical characteristics. Type 1 NETs are the most frequent (70 -80% of all cases) and associated with type -A chronic atrophic gastritis. Type II NETs are rare and occur in association with Zollinger -Ellison syndrome in multiple endocrine neoplasia type I (MEN-1). Type III NETs are the second most common and occur in a sporadic and solitary large form. Our case had Helicobacter pylori positive gastritis, and his tumor is classified into type III NET.
Apart from the regional lymph nodes, the liver is the most frequent site of NET and liver metastases are major prognostic factor of NET (14) . Our patient with gastric NET G2 developed liver metastasis 11 months after gastrectomy. Shin et al. reported that one of eight patients who have gastric NET with liver metastases was G2 and others were NEC (15) . Another factor, like unknown primary tumor as reported (15) , other than histological grade may affect the prognosis.
61 cases of gastric endocrine carcinoma were reported with description or in the photo of the upper gastrointestinal endoscope. 13 cases (21%) were Borrmann type I, 25 cases (40%) were type II, 15 cases (24%) were type III, 1 case was type IV, 1 case was type V, and 5 cases were type 0 (IIa 1 case ; IIc 3 cases ; IIa+ IIc 1 case). One case showed the morphology of submucosal tumor. A rare polypoid type early NEC in the stomach was reported (16) . Endoscopic findings of the tumor also demonstrated a polypoid lesion with a broad stalk. The surface showed a white coat, erosion and lobulation and the macroscopic finding was unique and similar with the one of our case. The mass of our case is whitish Borrmann I and looks like cauliflower. The tumor infiltrated into the subserosa in association with lymphangioinvasion. Gastric NEC arises predominantly from endocrine precursor cell clones that develop in the preceding adenocarcinoma component. These clones transform into NEC and the NEC develops rapidly in the submucosal and deeper layer (17). According to the histological examination, a wide range of necrosis by the metastatic cancer was observed in the lymphatic ducts of the tumor. Probably those things contribute to the color and the shape of the tumor.
Treatment of localized gastric NETs usually involves surgical resection, and surgery is the only curative treatment for NETs. Chemotherapy has recently been recommended to be administered to NEC patients following gastrectomy. There is no standardized chemotherapy for gastric NET. Chemotherapeutic regimens including cisplatin, irinotecan, etoposide, doxorubicin, and vincristine are reported. Kulke et al. (18) reported a very low response rate to cisplatin plus irinotecan for extra-pulmonary NETs, however, Okita et al. (10) reported the response rate to cisplatin plus irinotecan for gastric poorly differentiated NEC was 75%. Large -scale retrospective analyses for advanced neuroendocrine carcinoma of the digestive system by Japanese group demonstrate that irinotecan plus cisplatin (IP) and etoposide plus cisplatin (EP) are the most commonly used regimens (19) . IP was the most commonly selected regimen, especially for the gastrointestinal tract in the Japanese study (19) , while EP was the most commonly selected regimen in the Nordic study (20) . The response rate of IP was slightly better than that of EP for the treatment of NEC, even after adjusting patient background by multivariate analysis. The median overall survival of gastric NEC patients is 13.3 months. We chose IP chemotherapy and the overall survival of our case was much longer, although the tumor is classified into NET G2 and our case is hard to compare with the cases of NEC simply. Because a part of NET G2 actually embraces a very aggressive profile and has rather a G3 -NET-like behavior, chemotherapy might become the first option therapy (21) . However, gastric NETs are not discussed in independent, large-scaled prospective studies and tend to be excluded from clinical trials, because the cases are few (22) . Systematic study of the treatment for NET G2 of digestive system should be considered in the future.
Somatostatin analogues (SSAs) have shown to be effective in the treatment of midgut NETs (23) . Type I and II gastric NETs are gastrin-dependent and associated with conditions inducing hypergastrinemia. SSAs have been increasingly used in the treatment of patients with type I and II gastric NETs (24) , based on their capability to lower the elevated gastrin levels and suppress enterochromaffin like cell hyperplasia. As stated above, our case seemed to belong to type III gastric NET and serum gastrin level in our case was within normal range (our case 184 pg/ml ; normal values 42 -200 pg/ml) (11, 25) . Management of type III gastric NET is comparable to that used for gastric adenocarcinomas. SSAs are considered to be a beneficial treatment in well-differentiated NET G1 and might also be applied to control clinical symptoms in NET G2 with higher proliferation like our case (26) .
Interferon alpha along with SSAs has been used as a treatment of midgut NETs, although often with potentially high toxicity (27) . Everolimus, an inhibitor of mammalian target of rapamycin (mTOR), and sunitinib, an inhibitor of multi-targeted tyrosine kinase, are reported to give a statistically significant survival benefit in enteropancreatic NET (28, 29) .
Recently, bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), has shown promising results in gastroenteropancreatic NETs, because gastroenteropancreatic neuroendocrine tumors are known as hypervascular tumors with increased expressions of VEGF and VEGF receptors (30, 31) . Table  1 summarizes clinical trials for gastroenteropancreatic NET G1/ G2. The combination with bevacizumab, SSAs, cytotoxic chemotherapy or mTOR inhibitors may be a promising strategy in the patients with gastric NET G1/G2. 
